Energy-device maker posts $0.02 earnings beat as U.S. device demand remains steady.
InMode reported Q2 2026 earnings that beat consensus by $0.02 per share, with revenue topping Wall Street estimates. The RF microneedling and energy-device platform maker continues to benefit from steady U.S. aesthetic device demand, though margin compression concerns persist in analyst commentary.
The company's core installed base of Morpheus8 and BodyTite systems remains a revenue anchor, but competitive pressure from Cutera and other multi-modality platforms is intensifying. Steel Partners, InMode's largest shareholder, has publicly urged shareholders to vote against certain governance proposals, signaling activist pressure over capital allocation and strategic direction.
InMode beats EPS by $0.02; margin compression concerns persist.
For practice owners evaluating device ROI, InMode's beat underscores that installed-base revenue and service contracts still drive profitability—but the margin squeeze is real. Watch the next quarter's gross margin trend closely; device-only players without strong recurring revenue models face headwinds.
Source: original report ↗
Frequently asked questions
Is InMode Morpheus8 still worth buying in 2026?
InMode beat Q2 earnings by $0.02 per share with revenue above estimates, driven by steady U.S. aesthetic device demand and a strong installed base of Morpheus8 and BodyTite systems. However, margin compression is a growing concern, so ROI depends heavily on your ability to build recurring revenue through service contracts and installed-base upsells rather than device sales alone.
What's happening with InMode's profit margins?
InMode is experiencing margin compression despite beating earnings, which analysts are flagging as a persistent concern. Practice owners should monitor the company's gross margin trend closely in upcoming quarters, as device-only players without strong recurring revenue models face increasing headwinds.
How does InMode compete against Cutera and other device makers?
InMode's Morpheus8 and BodyTite systems remain revenue anchors, but competitive pressure from Cutera and multi-modality platforms is intensifying. InMode's advantage lies in its installed base and service contract revenue, but practices should evaluate whether competitors' multi-modality offerings provide better long-term ROI.
What does Steel Partners' activist push mean for InMode shareholders?
Steel Partners, InMode's largest shareholder, has publicly urged shareholders to vote against certain governance proposals, signaling activist pressure over capital allocation and strategic direction. This suggests potential changes to how the company deploys capital and manages growth, which could affect device pricing and support for practices.
Should I focus on device sales or service contracts for InMode ROI?
InMode's Q2 beat demonstrates that installed-base revenue and service contracts drive profitability more reliably than device sales alone. Practice owners should prioritize building recurring revenue through maintenance contracts and service agreements to offset margin compression in the device market.
Stay three moves ahead of every practice in your market.
Knowing it happened is table stakes. Inside MedSpa Pro hands you the play — what each move means for your margins, your license, and your patients, and exactly what to do about it — in a two-minute brief, twice a week. The owners who read it never get blindsided.
Get the edge · $20/mo
Join the owners who run ahead of the industry. Cancel anytime, one click.
